Trials / Completed
CompletedNCT01527370
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in India
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 250 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
This study will determine if ZOSTAVAX™ is safe, tolerable, and immunogenic in healthy adults in India.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Zoster Vaccine Live | One approximately 0.65 mL injection subcutaneously on Day 1 |
Timeline
- Start date
- 2012-10-31
- Primary completion
- 2013-04-09
- Completion
- 2013-04-09
- First posted
- 2012-02-07
- Last updated
- 2018-09-18
- Results posted
- 2013-12-30
Source: ClinicalTrials.gov record NCT01527370. Inclusion in this directory is not an endorsement.